Karyopharm Therapeutics secures $10 million in Seires A2 financing

Wednesday, November 2, 2011

Karyopharm Therapeutics has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione. This brings the total raised by the company to approximately $32M since its inception. The funds will be used to expand the planned phase I program, targeted to begin in mid 2012 with Karyopharm’s oral selective inhibitors of nuclear export (SINE) for various cancers. The company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

[Read More]